BioCorRx Business Summary

BioCorRx Inc. (BICX) is a commercial-stage biotechnology company specializing in medication-assisted treatment (MAT) for substance use disorders and weight management. The company generates revenue through three primary segments: the commercial distribution of LUCEMYRA (lofexidine), an FDA-approved non-opioid treatment for opioid withdrawal acquired in March 2025; the Beat Addiction Recovery Program, which licenses proprietary cognitive behavioral therapy (CBT) modules and peer support platforms to independent clinics; and the UnCraveRx Weight Loss Management Program, a medically assisted weight loss solution integrated with a virtual behavioral support application. Its clinical pipeline is led by BICX104, an implantable, sustained-release naltrexone pellet designed for long-term relapse prevention in patients with opioid and alcohol use disorders, supported by multi-million dollar grants from the National Institute on Drug Abuse (NIDA). BioCorRx competes directly with established pharmaceutical players such as Alkermes plc (ALKS), Indivior (INDV), and Titan Pharmaceuticals (TTNP), positioning itself as a niche provider of integrated, long-acting therapeutic solutions that combine pharmacological intervention with digital behavioral health support. Lourdes Felix serves as the Chief Executive Officer, Chief Financial Officer, and Director, having led the company since 2012 and co-founded its drug development subsidiary, BioCorRx Pharmaceuticals Inc. The leadership team was further strengthened in January 2026 with the appointment of Louis Lucido as Board Chair; Lucido previously served as the company’s President and was formerly the Senior Advisor and COO of DoubleLine Group. The Board of Directors includes high-profile finance and pharmaceutical veterans, such as Joseph J. Galligan, a founding partner of DoubleLine Capital, and Harsha Murthy, a managing partner at Consummate Capital with extensive experience at King Pharmaceuticals and GE Capital. Additionally, the company leverages the expertise of Dr. Kate Beebe DeVarney, a Director and Consultant for the pharmaceutical subsidiary and former President of Titan Pharmaceuticals, who brings over 30 years of experience in neurosciences and regulatory affairs to the company’s clinical development programs.